Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer

J. Lacour, F. Lacour, A. Spira, M. Michelson, J. Y. Petit, G. Delage, D. Sarrazin, G. Contesso, J. Viguier

Research output: Contribution to journalArticle

Abstract

Adjuvant immunotherapy with polyadenylic-polyuridylic acid (PolyA.PolyU) was tested in a randomised trial on 300 patients with operable breast cancer, all of whom were treated by surgery with or without radiotherapy. They were randomly divided into an experimental group of 155 patients who were treated with 30 mg PolyA.PolyU intravenously per week for 6 weeks and a control group of 145 patients who received normal saline intravenously on the same schedule. The mean follow-up time was more than 50 months in both groups. The overall survival was significantly higher in the treated group (p ≤ 0.05), in whom the 5-year 'relapse-free' survival was also increased. In node-positive patients, treatment increased the relapse-free survival (p ≤ 0.03) and overall survival (p ≤ 0.07). No side-effects were noted. Thus, immunotherapy with PolyA.PolyU appears to be a simple, non-toxic, and efficient adjuvant treatment in operable breast cancer.

Original languageEnglish
Pages (from-to)161-164
Number of pages4
JournalLancet
Volume2
Issue number8187
DOIs
Publication statusPublished - 1980

Fingerprint

Poly A-U
Breast Neoplasms
Survival
Immunotherapy
Recurrence
Therapeutics
Appointments and Schedules
Radiotherapy
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lacour, J., Lacour, F., Spira, A., Michelson, M., Petit, J. Y., Delage, G., ... Viguier, J. (1980). Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer. Lancet, 2(8187), 161-164. https://doi.org/10.1016/S0140-6736(80)90057-4

Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer. / Lacour, J.; Lacour, F.; Spira, A.; Michelson, M.; Petit, J. Y.; Delage, G.; Sarrazin, D.; Contesso, G.; Viguier, J.

In: Lancet, Vol. 2, No. 8187, 1980, p. 161-164.

Research output: Contribution to journalArticle

Lacour, J, Lacour, F, Spira, A, Michelson, M, Petit, JY, Delage, G, Sarrazin, D, Contesso, G & Viguier, J 1980, 'Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer', Lancet, vol. 2, no. 8187, pp. 161-164. https://doi.org/10.1016/S0140-6736(80)90057-4
Lacour, J. ; Lacour, F. ; Spira, A. ; Michelson, M. ; Petit, J. Y. ; Delage, G. ; Sarrazin, D. ; Contesso, G. ; Viguier, J. / Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer. In: Lancet. 1980 ; Vol. 2, No. 8187. pp. 161-164.
@article{5aeaacba4ac64c57886a7e06afac9fd2,
title = "Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer",
abstract = "Adjuvant immunotherapy with polyadenylic-polyuridylic acid (PolyA.PolyU) was tested in a randomised trial on 300 patients with operable breast cancer, all of whom were treated by surgery with or without radiotherapy. They were randomly divided into an experimental group of 155 patients who were treated with 30 mg PolyA.PolyU intravenously per week for 6 weeks and a control group of 145 patients who received normal saline intravenously on the same schedule. The mean follow-up time was more than 50 months in both groups. The overall survival was significantly higher in the treated group (p ≤ 0.05), in whom the 5-year 'relapse-free' survival was also increased. In node-positive patients, treatment increased the relapse-free survival (p ≤ 0.03) and overall survival (p ≤ 0.07). No side-effects were noted. Thus, immunotherapy with PolyA.PolyU appears to be a simple, non-toxic, and efficient adjuvant treatment in operable breast cancer.",
author = "J. Lacour and F. Lacour and A. Spira and M. Michelson and Petit, {J. Y.} and G. Delage and D. Sarrazin and G. Contesso and J. Viguier",
year = "1980",
doi = "10.1016/S0140-6736(80)90057-4",
language = "English",
volume = "2",
pages = "161--164",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "8187",

}

TY - JOUR

T1 - Adjuvant treatment with polyadenylic-polyuridylic acid (PolyA.PolyU) in operable breast cancer

AU - Lacour, J.

AU - Lacour, F.

AU - Spira, A.

AU - Michelson, M.

AU - Petit, J. Y.

AU - Delage, G.

AU - Sarrazin, D.

AU - Contesso, G.

AU - Viguier, J.

PY - 1980

Y1 - 1980

N2 - Adjuvant immunotherapy with polyadenylic-polyuridylic acid (PolyA.PolyU) was tested in a randomised trial on 300 patients with operable breast cancer, all of whom were treated by surgery with or without radiotherapy. They were randomly divided into an experimental group of 155 patients who were treated with 30 mg PolyA.PolyU intravenously per week for 6 weeks and a control group of 145 patients who received normal saline intravenously on the same schedule. The mean follow-up time was more than 50 months in both groups. The overall survival was significantly higher in the treated group (p ≤ 0.05), in whom the 5-year 'relapse-free' survival was also increased. In node-positive patients, treatment increased the relapse-free survival (p ≤ 0.03) and overall survival (p ≤ 0.07). No side-effects were noted. Thus, immunotherapy with PolyA.PolyU appears to be a simple, non-toxic, and efficient adjuvant treatment in operable breast cancer.

AB - Adjuvant immunotherapy with polyadenylic-polyuridylic acid (PolyA.PolyU) was tested in a randomised trial on 300 patients with operable breast cancer, all of whom were treated by surgery with or without radiotherapy. They were randomly divided into an experimental group of 155 patients who were treated with 30 mg PolyA.PolyU intravenously per week for 6 weeks and a control group of 145 patients who received normal saline intravenously on the same schedule. The mean follow-up time was more than 50 months in both groups. The overall survival was significantly higher in the treated group (p ≤ 0.05), in whom the 5-year 'relapse-free' survival was also increased. In node-positive patients, treatment increased the relapse-free survival (p ≤ 0.03) and overall survival (p ≤ 0.07). No side-effects were noted. Thus, immunotherapy with PolyA.PolyU appears to be a simple, non-toxic, and efficient adjuvant treatment in operable breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0018828863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018828863&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(80)90057-4

DO - 10.1016/S0140-6736(80)90057-4

M3 - Article

C2 - 6105336

AN - SCOPUS:0018828863

VL - 2

SP - 161

EP - 164

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8187

ER -